A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 10 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2019, as reported by ClinicalTrials.gov.
- 10 Aug 2015 Planned primary completion date changed from 1 Aug 2014 to 1 May 2015, as reported by ClinicalTrials.gov.
- 16 Aug 2012 New trial record